US · BBLG
Bone Biologics Corporation
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Burlington, MA 01803
- Website
- bonebiologics.com
Price · as of 2024-12-31
$1.31
Market cap 2.07M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $2,419.20 | ||||
| 2022 | $371.52 | ||||
| 2023 | $14.46 | ||||
| 2024 | $5.04 |
AI valuation
Our deep-learning model estimates Bone Biologics Corporation's (BBLG) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $1.31
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BBLG | Bone Biologics Corporatio… | $1.31 | 2.07M | — | — | — | — | -1.86 | 2.19 | — | 40.32 | — | 2.19 | 0.00% | — | — | -128.71% | -22020.98% | -108.23% | 0.00 | — | 10.22 | 8.80 | -31.03 | -8580.00% | — | -5683.00% | -53.95% | -10.92 | -21530.04% | 42.02% | -78.10% | 45.92% | -1.02 | -1.05 | — | -21.20 |
| BDRX | Biodexa Pharmaceuticals P… | $1.08 | 90.59K | +65,720% | — | — | — | -0.25 | 0.17 | — | -0.05 | -0.06 | 0.53 | 0.00% | — | — | -88.14% | -269.10% | -45.25% | 0.09 | — | 1.75 | 0.47 | 0.10 | 40524.00% | -10000.00% | 8388.00% | -924.24% | -2.44 | -397.95% | 0.00% | 0.00% | 0.00% | -0.05 | -0.04 | — | -15.86 |
| DHAI | DIH Holding US, Inc. | $0.00 | 5.23K | +1,170,700% | +87,500% | — | — | -903.76 | -211.15 | 124.73 | -1104.70 | — | -211.15 | 51.24% | -7.74% | -13.80% | 24.90% | 20.72% | -27.77% | -0.32 | -15.34 | 0.49 | 0.12 | -1.41 | -2412.00% | -250.00% | -19379.00% | -0.06% | -0.10 | 19.94% | 0.00% | 0.00% | 0.03% | -1614.12 | -1677.58 | 124.89 | 72.12 |
| GCTK | GlucoTrack, Inc. | $1.55 | 879.56K | — | — | — | — | -0.36 | -0.63 | — | -0.13 | — | -0.63 | 0.00% | — | — | 461.02% | 149.59% | -417.03% | -0.02 | -24.95 | 4.52 | 4.41 | 0.24 | -25864.00% | — | 9204.00% | -152.95% | -9.80 | 129.51% | 0.00% | 0.00% | 12.80% | -0.20 | -0.23 | — | -38.18 |
| HSCS | HeartSciences Inc. | $2.79 | 6.25M | +699% | -40% | — | +21,742% | -0.45 | 19.02 | 897.28 | -0.71 | — | -2.77 | -2884.71% | -192013.13% | -201499.52% | -233.04% | -360.16% | -127.72% | 14.55 | -16.69 | 0.59 | 0.30 | -0.23 | -5016.00% | -7661.00% | 2014.00% | -190.70% | -2.00 | -320.95% | 0.00% | 0.00% | 0.00% | -0.69 | -0.78 | 1331.10 | -31.62 |
| INM | InMed Pharmaceuticals Inc… | $0.85 | 1.54M | +1,918% | +653% | — | — | -0.25 | 0.11 | 0.42 | 1.66 | — | 0.13 | 34.53% | -160.20% | -165.14% | -52.84% | -173.20% | -43.65% | 0.06 | -21.22 | 6.99 | 6.27 | 1.94 | -5848.00% | 750.00% | 1103.00% | -377.16% | -3.10 | -169.90% | 0.00% | 0.00% | 311.23% | 1.52 | 1.55 | -2.43 | -10.26 |
| MOVE | Movano Inc. | $11.40 | 8.65M | — | — | — | — | -90.32 | 291.38 | 2115.60 | -88.77 | — | 291.38 | -196.84% | -2391.12% | -2342.25% | -439.23% | 1722.15% | -228.79% | 0.03 | — | 3.02 | 2.31 | 0.32 | -3810.00% | — | -1410.00% | -1.05% | -6.54 | 1602.63% | 0.00% | 0.00% | 0.08% | -88.16 | -94.73 | 2107.98 | 299.75 |
| NAOV | NanoVibronix, Inc. | $2.26 | 1.8M | +62,596% | +597% | — | — | -2.87 | 16.95 | 4.15 | -2.71 | — | 16.95 | 58.95% | -140.03% | -144.84% | -160.56% | -1021.97% | -71.92% | 0.19 | -26.53 | 1.22 | 0.37 | 0.17 | -3524.00% | 1205.00% | -3009.00% | -23.70% | -0.92 | -718.69% | 0.00% | 0.00% | 0.00% | -2.79 | -3.97 | 3.91 | -27.16 |
| NDRA | ENDRA Life Sciences Inc. | $4.15 | 3.12M | — | — | — | — | -0.34 | 1.54 | — | -0.12 | -0.46 | 1.54 | 0.00% | — | — | -280.02% | -690.14% | -205.38% | 0.23 | — | 5.67 | 5.34 | 0.25 | 7402.00% | — | -2260.00% | -188.25% | -12.23 | -473.18% | 0.13% | 0.00% | 5.35% | -0.12 | -0.17 | — | -38.53 |
| VERO | Venus Concept Inc. | $0.31 | 576.33K | +37,326% | +290% | — | +132,842% | -0.05 | 0.91 | 0.03 | -1.14 | -0.01 | -0.83 | 68.34% | -41.93% | -72.49% | 806.37% | -52.93% | -58.05% | 18.16 | -3.55 | 1.60 | 0.78 | -1.08 | 86901.00% | -1509.00% | -1376.00% | -520.15% | -0.37 | -22.07% | 0.00% | 0.00% | 1652.41% | -1.50 | -3.66 | 0.63 | -6.37 |
About Bone Biologics Corporation
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
- CEO
- Jeffrey Frelick
- Employees
- 2
- Beta
- 0.41
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $1.31) − 1 = — (DCF, example).